Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 4

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 8
Chunk 4
---
400,179  
     150,000 
  
    Other prepaid expenses 
     374,638  
     175,088 
  
    Total prepaid expenses and other current assets 
    $1,069,910  
    $831,577 
  
    Prepaid expenses and other current assets 
    $1,069,910  
    $831,577 

NOTE 4: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts payable and other current liabilities are
comprised of the following:

SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES 

    March 31, 2025  
    December 31, 2024 
  
    Accounts payable 
    $1,311,095  
    $870,229 
  
    Accrued employee costs 
     83,466  
     1,371,498 
  
    Accrued professional fees 
     69,959  
     72,054 
  
    Accrued research and development 
     898,067  
     860,958 
  
    Accrued board fees 
     117,750  
     117,750 
  
    Other accrued expenses 
     72,042  
     17,228 
  
    Total accounts payable and other current liabilities 
    $2,552,379  
    $3,309,717 

NOTE 5: STOCK-BASED COMPENSATION

The Company has an equity incentive plan for grants
to employees, officers, consultants, directors, and other service providers that was approved in 2021 (the “2021 Plan”). The
2021 Plan provides for the grant of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units,
unrestricted stock awards, stock appreciation rights and other forms of stock-based compensation. The 2021 Plan permits the Company’s
board to change the type, terms, and conditions of awards as circumstances may change. This flexibility to adjust the type of compensation
to be granted is particularly important given current economic and world events.

    F-7

A summary of the stock option activity during the
period ended March 31, 2025, is presented in the table below:

 SCHEDULE OF STOCK OPTION ACTIVITY 

    Weighted average  

    Number of  options  
    Exercise  price  
    Remaining  contractual  life  (in years